[1] Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2[J]. Cell, 1998, 92(4):441-450.
[2] Neel B G, Gu H, Pao L. The ‘Shp’ ing news:SH2 domain-containing tyrosine phosphatases in cell signaling[J]. Trends Biochem Sci, 2003, 28(6):284-293.
[3] Chang W, Gao X, Han Y, et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma[J]. Gut, 2014, 63(9):1457-1467.
[4] 罗虎, 周向东. SHP2及其在乳腺癌发生发展中的作用[J]. 生命的化学, 2010,30(6):833-837.
[5] Tartaglia M, Mehle E L, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome[J]. Nat Genet, 2001, 29(4):465-468.
[6] Higuchi M, Tsutsumi R, Higashi H, et al. Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity[J]. Cancer Sci, 2004, 95(5):442-447.
[7] Zhou X, Coad J, Ducatman B, et al. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis[J]. Histopathology, 2008, 53(4):389-402.
[8] 唐春兰, 周向东, 杨和平等. SHP2在非小细胞肺癌中的表达及意义[J]. 中国肺癌杂志, 2010, 13(2):98-101.
[9] Martinelli S, Carta C, Flex E, et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors[J]. Cancer Genet Cytogenet, 2006, 166(2):124-129.
[10] Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia[J]. Cancer Res, 2004, 64(24):8816-8820.
[11] Sartore-Bianchi A, Siena S. Plasticity of resistance and sensitivity to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer[J]. Handb Exp Pharmacol,2017,DOI: 10.1007/164_2017_19.
[12] Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells[J]. Cell Death Differ, 2006, 13(2):202-211.
[13] Dai Y, Jiao H, Teng G, et al. Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling[J]. Mol Cancer Ther, 2014, 13(5):1206-1216.
[14] Chu EC, Chai J, Tarnawski AS. NSAIDs activate PTEN and other phosphatases in human colon cancer cells:novel mechanism for chemopreventive action of NSAIDs[J]. Biochem Biophys Res Commun, 2004, 320(3):875-879.
[15] Östman A, Hellberg C, Böhmer FD. Protein-tyrosine phosphatases and cancer[J]. Nat Rev Cancer, 2006, 6(4):307-320.
[16] Li S, Hsu DD, Wang H, et al. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis[J]. Front Med, 2012, 6(3):275-279.
[17] Jakob S, Schroeder P, Lukosz M, et al. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase[J]. J Biol Chem, 2008, 283(48):33155-33161.
[18] Ran H, Kong S, Zhang S, et al. Nuclear Shp2 directs normal embryo implantation via facilitating the ERα tyrosine phosphorylation by the Src kinase[J]. Proc Natl Acad Sci USA, 2017, 114(18):4816-4821.
[19] Yuan L, Yu WM, Yuan Z, et al. Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response[J]. J Biol Chem,2003,278(17):15208-15216.